Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk

Michelle L. ODonoghue,Sergio Fazio,Robert P. Giugliano,Erik S.G. Stroes,Estella Kanevsky,Ioanna Gouni Berthold,KyungAh Im,Armando Lira Pineda,Scott M. Wasserman,Češka R,M. Ezhov,J. Wouter Jukema,Henrik Jensen,S.Lale Tokgözoğlu,Francois Mach,Kurt Huber,Peter Sever,Anthony Keech,Terje R. Pedersen,Marc S. Sabatine

Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk

2019

Background: Lipoprotein(a) [Lp(a)] may play a causal role in atherosclerosis. PCSK9 (proprotein convertase subtilisin/kexin 9) inhibitors have been shown to significantly reduce plasma Lp(a) concen...

Keywords:

Lipoprotein(a)
Proprotein convertase
Internal medicine
Endocrinology
Kexin
Cardiology
Subtilisin
Diabetes mellitus
Medicine
PCSK9
Lipoprotein

Correction
Cite
Save
Machine Reading By IdeaReader

References

Citations